Skip to content

A single center retrospective cohort study: The effectiveness and safety of different doses of rivaroxaban vs. warfarin and no anti-coagulation drugs in the treatment of left ventricular thrombus caused by coronary heart disease in the real world

The effectiveness and safety of different doses of rivaroxaban in the treatment of left ventricular thrombus caused by coronary heart disease in the real world

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500107034
Enrollment
Unknown
Registered
2025-08-01
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The thrombus in the left ventricle

Interventions

The test group-the group with normal dosage of rivaroxaban:None
The test group-the group with small dosage of rivaroxaban:None
The control group- the warfarin group:None
The control group- no anticoagulation group:None

Sponsors

Tianjin chest hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients with LVT caused by coronary heart disease (The formation of LVT occurring in a low-flow and low-shear environment). Patients with more than two TTE follow-ups. Patients discharged alive.

Exclusion criteria

Exclusion criteria: Patients with LVT caused by non-coronary heart disease. Patients with LVT involving mechanical circulatory assist devices (The formation of LVT is predominantly in contact pathway but not mediated in a low-flow and low-shear environment ). Patients died during the index hospitalization or died before oral anticoagulants taking effect. Patients who were lost to follow up, refused to follow up or followed up with less than two times of TTE. Patients with LVT disappeared during only subcutaneous LMWH injection. Patients with other oral anticoagulants such as dabigatran, apixaban. Patients with severe renal failure [creatinine clearance (CrCl) < 15 mL/min] and severe liver diseases (transaminase exceeded the reference value by more than 3 times).However, severe liver and kidney function damage caused by transient reasons were not excluded. Patients with technically limited 2D-TTE, which prevented assessment of the presence of thrombus. Pregnancy and confirmed hematologic diseases (except mild or moderate anemia).

Design outcomes

Primary

MeasureTime frame
The resolution rate of left ventricular thrombus;

Secondary

MeasureTime frame
The rate of composite endpoints;The rate of embolism;The rate of bleeding;The rate of death ;The rate of major adverse cardiovascular events (MACE);

Countries

China

Contacts

Public ContactWei Zhang

Tianjin chest hospital

wei.229@163.com+86 185 2272 8236

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026